NEW YORK – January 11, 2025 (NEWMEDIAWIRE) – Kaplan Fox & Kilsheimer LLP publicizes {that a} class motion lawsuit has been filed in opposition to Revance Therapeutics (NASDAQ:), Inc. (Revance or the Firm) (NASDAQ: RVNC) on behalf of traders that bought or in any other case acquired Revance securities between February 29, 2024 and December 6, 2024 (the Class Interval).
CLICK HERE TO JOIN THE CASE
If you’re an investor in Revance and have suffered losses, you could CLICK HERE to contact us. You may additionally contact Kaplan Fox by emailing pmayer@kaplanfox.com or by calling (646) 315-9003.
DEADLINE REMINDER: If you’re a member of the proposed Class, you could transfer the courtroom no later than March 4, 2025 to function a lead plaintiff for the purported class. If in case you have losses we encourage you to contact us to study extra in regards to the lead plaintiff course of.
Revance is a biotechnology firm and the distributor of sure dermal filler merchandise pursuant to an unique distribution settlement with Teoxane SA.
On August 12, 2024, Revance issued a press release saying that the Firm had entered right into a merger settlement with Crown Laboratories (Crown). Underneath the phrases of the settlement, the press release indicated that Crown would start a young provide to amass all excellent shares of Revances widespread inventory for $6.66 per share (the Tender Supply).
Then, on September 23, 2024, Revance disclosed that it acquired a discover to treatment alleged materials breaches, together with breaches of the utmost ranges of buffer inventory and required efforts to advertise and promote Teoxane merchandise, underneath the Companys unique distribution settlement with Teoxane SA. As a result of dispute with Teoxane, the Firm suggested that Crowns Tender Supply had been delayed till at the very least October 4, 2024.
On this information, the price of Revance inventory fell $.445 per share, or 7.66%, to shut at $5.365 per share on September 23, 2024.
Then, on December 9, 2024, the Firm disclosed that Crown and Revance had amended their merger settlement, and that Crown would start a young provide on December 12, 2024 to amass all excellent shares of Revance widespread inventory for $3.10 per share, greater than 50% decrease than the unique buy price.
On this information, the price of Revance inventory fell $.79 per share, or 20.68%, to shut at $3.03 per share on December 9, 2024.
The grievance alleges, amongst different issues, that all through the Class Interval, Defendants made false and/or deceptive statements and/or didn’t disclose that (i) Revance was in materials breach of the Distribution Settlement; (ii) the foregoing subjected the Firm to an elevated danger of litigation, in addition to financial and reputational hurt; and (iii) all of the foregoing elevated the danger that the Tender Supply could be delayed and/or amended.
WHY CONTACT KAPLAN FOX – Kaplan Fox is a number one nationwide legislation agency specializing in complicated litigation with places of work in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of expertise in securities litigation, Kaplan Fox affords the skilled expertise and monitor document that shoppers demand. By prosecuting instances on the federal and state ranges, Kaplan Fox has efficiently formed the legislation by means of profitable many essential selections on behalf of our shoppers. For extra details about Kaplan Fox & Kilsheimer LLP, you could go to our web site at www.kaplanfox.com .
This press release could also be thought-about Legal professional Promoting in some jurisdictions underneath the relevant legislation and moral guidelines.
If in case you have any questions on this Discover, your rights, or your pursuits, please contact:
CONTACT:
Pamela A. Mayer
KAPLAN FOX & KILSHEIMER LLP
800 Third Avenue, thirty eighth Flooring
New York, New York 10022
(646) 315-9003
pmayer@kaplanfox.com
Laurence D. King
KAPLAN FOX & KILSHEIMER LLP
1999 Harrison Avenue, Suite 1560
Oakland, California 94612
(415) 772-4704
lking@kaplanfox.com
View the unique launch on www.newmediawire.com
Copyright 2025 JCN Newswire . All rights reserved.